Janice Cowden, MBC Patient Advocate, shared an update from Sarah Sammons, Co-Leader of Breast Oncology at UMGCCC, on X, adding:
“Speaking of those who ‘don’t mind IV therapy’… today I’m thinking of my good friend Ruth, who died from metastatic breast cancer in 8/2022. Because she couldn’t swallow pills, oral targeted tx options for her HR+/HER2- MBC weren’t possible. She was limited to IV chemotherapy, and would have been thrilled to see a targeted IV therapy finally become available.”
Quoting Sarah Sammons:
“Post-CDK4/6i, PIK3CA-WT HR+/HER2- MBC: how does gedatolisib stack up to other options?
PFS by regimen:
- Everolimus + ET: 5.5 mo Oral SERD alone (ESR1m): 5.5-8 mo
- Abema + imlunestrant: 10.9 mo
- Gedatolisib + fulv: 7.4 vs 2.0 mo, HR 0.33
- Gedatolisib + fulv + palbo: 9.3 vs 2.0 mo, HR 0.24
Not a clean cross-trial comparison, different populations and control arms. Clearly looks better than everolimus combo, though this should have been control.”
You might be interested in:
